Immunogenicity of recombinant envelope glycoproteins derived from T-cell line-adapted isolates or primary HIV isolates: A comparative study using multivalent vaccine approaches

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue 5, 2001, Pages 413-422

  Lemiale, Franck ^a   Brand, Denys ^a,c   Lebigot, Sarah ^a   Verrier, Bernard ^b   Buzelay, Laurence ^a   Brunet, Sylvie ^a   Barin, Francis ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITÉ DE LYON   (France)

^c EA 2639 Fac de Med 2 Bis   (France)

Author keywords

Immunogenicity; Recombinant HIV 1 envelope glycoproteins

Indexed keywords

GLYCOPROTEIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ARTICLE; CELL LINE; COMPARATIVE STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOASSAY; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; SEMLIKI FOREST ALPHAVIRUS; T LYMPHOCYTE; VIRUS ISOLATION; VIRUS RECOMBINANT;

EID: 0035870527     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200104150-00003     Document Type: Article

References (35)

1. Burton DR. A vaccine for HIV type 1: the antibody perspective. Proc Natl Acad Sci USA 1997;94:10018-23.
2. Montefiori DC, Evans TG. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Res Hum Retroviruses 1999;15:689-98.
3. Korber BT, Allen EE, Farmer AD, et al. Heterogeneity of HIV-1 and H1V-2. AIDS 1995;9(Suppl A):S5-11.
4. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: A RANTES, MIP-α1. MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-8.
5. Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-48.
6. Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 1996;272:872-7.
7. Simmons G, Wilkinson D, Reeves JD, et al. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lester or CCR5 as coreceptors for virus entry. J Virol 1996;70:8355-60.
8. Beddows S, Louisirirochanakul S, Cheingsong-Popov R, et al. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. J Gen Virol 1998;79:77-82.
9. Bou-Habib DC, Roderiquez G, Oravecz T, et al. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994;68:6006-13.
10. Moore JP, Cao Y, Qing L, et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120. and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995;69: 101-9.
11. Spenlehauer C, Saragosti S, Fleury HJA, et al. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell -line-adapted strains of human immunodeficiency virus type 1. J Virol 1998;72:9855-64.
12. Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gp 120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-59.
13. Weissenhorn W, Dessen A, Harrison SC, et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997;387:426-30.
14. Wyat R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998;393:705-11.
15. Earl PL, Doms RW, Moss B. Oligomeric structure of the human immunodeficiency virus type 1 envelope alycoprotein. Proc Natl Acad Sci USA 1990;87:648-52.
16. Reiter JN, Means RE, Desrosier RC. A role for carbohydrates in immune evasion in AIDS. Nat Med 1998;4:679-84.
17. Earl PL, Broder CC, Long D, et al. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibodies reactivities. J Virol ;68:3015-26.
18. Fouts TR, Binley JM, Trkola A, et al. Neutralization of the human immunodeficiency virus type I primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol 1997;71:2779-85.
19. Bolmstedt A, Sjölander S, Hansen J-ES, et al. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:213-20.
20. LaCasse RA, Follis KE, Trahey M, et al. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 1999;283:357-62.
21. Stamatatos L, Cheng-Mayer C. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J Virol 1998;72:7840-5.
22. Bradney AP, Scheer S, Crawford JM, et al. Neutralization escape in human immunodeficiency virus type 1-infected long-term non-progressors. J Infect Dis 1999;179:1264-7.
23. Moog C, Fleury HJA, Pellegrin I, et al. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997;71:3734-41.
24. Carotenuto P, Looij D, Keldermans L, et al. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 1998;12: 1591-1600.
25. Brand D, Lemiale F, Turbica I, et al Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a vaccine DNA, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles. AIDS Res Hum Retroviruses 1998;14:1369-77.
26. Mossman SP, Bex F, Berglund P, et al. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol 1996;70:1953-60.
27. Zhou X, Berglund P, Rhodes G, et al. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 1994;12: 1510-14.
28. Ataman-Onal Y, Coiffier C, Giraud A, et al. Comparison of complete env gene sequences from individuals with symptomatic primary HIV type 1 infection. AIDS Res Hum Retroviruses 1999;15: 1035-9.
29. Brand D, Lemiale F, Thibault G, et al. Antigenic properties of recombinant envelope glycoproteins derived from T-cell line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity. Virology 2000;271: 350-62.
30. Berglund P, Sjöberg M, Garoff H, et al. Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Bio/Technology 1993;11:916-20.
31. Liljeström P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Bio/Technology 1991;9:1356-61.
32. Moore JP, McCutchan FE, Poon S-W, et al. Exploration of antigenic variation in gp120 from clade A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 1994:68:8350-64.
33. Verrier FC, Chameau P, Altmeyer R, et al. Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependant cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate. Proc Natl Acad Sci USA 1997;94:9326-31.
34. Verrier F, Borman AM, Brand D, et al. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage. AIDS Res Hum Retroviruses 1999;15:731-43.
35. Trkola A, Pomales AB, Yuan H, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995; 69:6609-17.